UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 (State or other jurisdiction of incorporation or organization) Suite 310 - 815 W. Hastings Street, Vancouver, B.C. (Address of Principal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended September 30, 2020 or For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Suite 310 - 815 W. Hastings Street, Vancouver, B.C. Canada V6C 1B4 (A ...

InMed Pharmaceuticals Inc. (IMLFF) Q4 2020 Earnings Conference Call September 8, 2020 11:30 AM ET Company Participants Brendan Payne - Director, Investor Relations Eric Adams - President & Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President, Pre-Clinical Research & Development Alexandra Mancini - Senior Vice President, Clinical & Regulatory Affairs Conference Call Participants Maxim Jacobs - Edison Group Operator Good morning. My name is Veronica, and IÂ'll be yo ...

U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Corporate Presentation September 2020 www.inmedpharma.com :IN :IMLFF Disclaimers This presentation does not constitute an offering to sell or a solicitation of an offer to buy securities and the information contained herein is subject to the information contained in the Company's continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and operations of the Company included in this prese ...

InMed Pharmaceuticals Inc. (IMLFF) Q3 2020 Earnings Conference Call May 14, 2020 11:30 AM ET Company Participants Brendan Payne – Director-Investor Relations Eric Adams – President and Chief Executive Officer Bruce Colwill – Chief Financial Officer Alexandra Mancini – Senior Vice President-Clinical and Regulatory Affairs Eric Hsu – Senior Vice President-Preclinical Research and Development Conference Call Participants Scott Henry – ROTH Capital Jim Molloy – Alliance Global Max Jacobs – Edison Group Operator ...

U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Investor Presentation May 2020 www.inmedpharma.com :IN :IMLFF 2 Disclaimers This presentation does not constitute an offering to sell or a solicitation of an offer to buy securities and the information contained herein is subject to the information contained in the Company's continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and operations of the Company included in this presentati ...

U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Investor Presentation February 2020 www.inmedpharma.com :IN :IMLFF 2 Disclaimers This presentation does not constitute an offering to sell or a solicitation of an offer to buy securities and the information contained herein is subject to the information contained in the Company's continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and operations of the Company included in this prese ...

InMed Pharmaceuticals Inc. (IMLFF) Q2 2020 Earnings Conference Call February 14, 2020 11:30 AM ET Company Participants Brendan Payne - Director of Investor Relations Eric Adams - President & Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President of Pre-Clinical R&D Alexandra Mancini - Senior Vice President of Clinical & Regulatory Affairs Michael Woudenberg - Vice President-Chemistry, Manufacturing & Controls Conference Call Participants Maxim Jacobs - Edison Group ...

Company Overview - InMed is focused on developing cannabinoid pharmaceuticals for diseases with high unmet medical needs, researching rare cannabinoids beyond THC & CBD [11] - The company is developing a biosynthetic manufacturing approach to achieve low-cost production of biologically identical cannabinoids [11] - The company's cash equivalents and short-term investments were C$14.8 million (US$11.2 million) as of September 30, 2019 [36] INM-755 for Epidermolysis Bullosa (EB) - INM-755 is being investigated for symptomatic relief in all EB patients, potentially accelerating wound healing, reducing pain and itch, and reducing inflammation [21] - Clinical trials for INM-755 include Phase I studies in healthy volunteers and Phase I/II studies in EB patients [23] - The company initiated a Phase 1 trial (755-101-HV) [24] INM-088 for Glaucoma - INM-088 targets reducing intraocular pressure (IOP) and providing neuroprotection for retinal ganglion cells (RGCs) in glaucoma [27] - The company plans to complete formulation development and proof-of-concept animal studies in the first half of 2020 [28] Manufacturing and Intellectual Property - The company is developing a proprietary biosynthesis process for cannabinoid manufacturing, offering cost savings and enhanced purity compared to extraction from plants or chemical synthesis [13, 16] - The company has a patent portfolio including methods for treating EBS with cannabinoids (INM-755) and cannabinoid-based therapy for glaucoma (INM-088) [31] - The company has 172.3 million shares outstanding [36]

InMed Pharmaceuticals Inc. (IMLFF) Q4 2019 Earnings Conference Call September 19, 2019 10:00 AM ET Company Participants Bruce Colwill - Chief Financial Officer Eric Adams - President & Chief Executive Officer Alexandra Mancini - Senior Vice President of Clinical & Regulatory Affairs Eric Hsu - Senior Vice President of Pre-Clinical R&D Michael Woudenberg - Vice President-Chemistry, Manufacturing & Controls Conference Call Participants Max Jacobs - Edison Group Jerry Isaacson - ROTH Capital George Ingram - In ...